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Useful Outcome Measures in Cardiovascular Medicine?*Jack V. Tu, MD, PHDT he burden of deaths from diseases such asischemic heart diseases (IHD) and acutemyocardial infarction (AMI) are assessed us-
ing a variety of outcomes measures. At the commu-
nity level, age-adjusted death rates from IHD can be
tracked as a cross-sectional measure of the burden
of disease. At a clinical level, 30-day AMI case-
fatality rates often are used as a preferred metric to
assess the quality and outcomes of acute cardiac
care. Although both of these measures are readily un-
derstandable to clinicians and policymakers, they
have important limitations. Overall population death
rates weight each death equally regardless of the age
of occurrence, and tend to be driven by diseases of
the elderly, where the vast majority of deaths occur
(a death at age 90 years is given the same weight as
a death at age 30 years). Improved AMI case-fatality
rates from medical interventions are important, but
do not consider the impact on life expectancy, which
may be a more relevant measure to patients and their
families. Some research has suggested that clinicians’
bedside estimates of life expectancy may explain the
“treatment-risk” paradox, whereby patients who
appear to have high short-term mortality risks are
less likely to receive clinically indicated therapies (1).
Because the prevention of premature mortality is
considered a worthwhile public health objective,*Editorials published in the Journal of the American College of Cardiology
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Foundation of Ontario.alternative measures of disease burden have been
developed. A commonly used summary measure of
premature mortality in population epidemiology is
years of potential life lost (YPLL) (2). The U.S. Centers
for Disease Control and Prevention (CDC) has re-
ported YPLL since 1982, and it is also used by many
other public health organizations (3). Typically, YPLL
can be calculated by subtracting the age at which an
individual dies from the projected life expectancy,
then summing these values across a population and
dividing it by the population at risk (2,4). Deaths at
the youngest ages are given the greatest weight.
The age of 75 years is often used as a reference life
expectancy for both men and women, with deaths
before this age considered premature, although other
age cutoffs, such as age 65 years, also have frequently
been used. Alternative methods for calculating YPLL
use life tables to calculate an age-speciﬁc life expec-
tancy for deaths at different ages rather than a ﬁxed
life expectancy (4). Cardiovascular diseases, cancer,
and accidents are the leading causes of YPLL in the
United States when using YPLL before age 75 years as
a measure of the burden of premature deaths (5).
Using data derived from the CDC, Figure 1 from the
National Center for Health Statistics, shows U.S.
temporal trends between 1980 and 2010 in YPLL
before the age of 75 years from IHD (5). Striking de-
clines in the YPLL in both sexes and by race are
observed over time, with a substantial narrowing of
differences between males and females. These trends
highlight the gains that have been achieved in pre-
venting premature IHD mortality in the United States
and are likely a reﬂection of several factors including:
1) a decrease in the incidence of new ischemic events
because of better risk factor detection and control;
and 2) improved case-fatality rates because of the
availability of newer treatments (6). By this measure
FIGURE 1 Years of Potential Life Lost Before Age 75 From Ischemic Heart Disease by
Sex and Race, United States, 1980-2010
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657of YPLL, males have a greater burden of premature
mortality than females, and blacks have a greater
burden than whites.3000
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Data source: National Center for Health Statistics. Health, United States, 2013: With
Special Feature on Prescription Drugs. Hyattsville, Maryland. 2014.
SEE PAGE 645In this issue of the Journal, Bucholz et al. (7) use
an alternative cohort-based method to estimate the
YPLL that are due to AMI for men and women, and
blacks and whites. The authors used data from the
Cardiovascular Cooperative Project, a large nation-
wide prospective cohort study of 146,743 elderly
Medicare patients hospitalized across the United Sates
from 1994 to 1995, with follow-up conducted through
linkage to administrative databases. Because approx-
imately 10% of patients had not died during the
follow-up period, it was necessary to use statistical
methods to extrapolate survival curves beyond the
17 years of follow-up that were available. From the
areas under the survival curves, they were able to es-
timate the average age-speciﬁc life expectancy for AMI
patients across a variety of age spans, ranging from 65
to 97 years. For benchmarking purposes, they also
used data from the Medicare administrative databases
to determine the age-speciﬁc life expectancy for
whites and blacks, and men and women in the general
population. The authors conclude that at the age of 65,
white women lose 4.9 years more of life after an AMI
than white men, and black women lose 5 years more of
life than black men. The differences between their
conclusions and the CDC data are due in part to taking
into account the fact the women live longer in the
general population than men, which highlights the
sensitivity of YPLL to the calculation methods uti-
lized. Their analyses reinforce the need to improve the
clinical presentation and treatment of all AMI patients
but especially those of black race. They also demon-
strate that the sex differences in YPLL are primarily
due to differences in life expectancy in the general
population rather than in the post-AMI population.
The estimation of life expectancy and YPLL from
large clinical trial or observational cohort databases
offers advantages over the life table methods tradi-
tionally used in epidemiology. These include not
requiring everyone to have passed away during the
follow-up period, and the ability to use regression
modeling techniques to statistically adjust for the
impact of patient characteristics and treatments on
projected life expectancy. However, the major disad-
vantage of these methods is that they require extrap-
olation of the survival function beyond the follow-up
period, and various statistical assumptions need to be
made about the nature of the survival curve. Some
empirical research has been conducted using clinical
databases to validate survival projections usingalternative statistical methods, but more research is
required to determine the optimal methods for doing
so (8,9).
The development of advanced methods to estimate
life expectancy using large clinical databases also has
other potential applications. For example, the pro-
jected impact on life expectancy and the cost effec-
tiveness of new drug therapies or device therapies
can be calculated from clinical trial data (10). Accurate
life expectancy estimates would also prove invalu-
able to clinicians in making decisions about use of
life-extending therapies in high-risk patients, such as
use of implantable cardioverter deﬁbrillators in
chronic heart failure patients or transcatheter aortic
valve replacement procedures in elderly aortic ste-
nosis patients (9,11,12). Life expectancy and YPLL are
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658infrequently used outcome measures in the ﬁeld of
clinical cardiovascular medicine. They will become
more widely used in the future as the population
ages, and the need for accurate estimates of life ex-
pectancy increases.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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